Literature DB >> 9877499

Heterogeneous point mutations of the p53 gene in pulmonary fibrosis.

S Hojo1, J Fujita, I Yamadori, T Kamei, T Yoshinouchi, Y Ohtsuki, H Okada, S Bandoh, Y Yamaji, J Takahara, T Fukui, M Kinoshita.   

Abstract

Lung cancer is a frequent complication in pulmonary fibrosis. Overexpression of p53 proteins has been demonstrated by immunostaining in bronchoepithelial cells in patients with idiopathic pulmonary fibrosis. However, it is still unclear whether this overexpressed p53 protein is wild-type or mutant. It was hypothesized that pulmonary fibrosis may be a precancerous lesion with deoxyribonucleic acid point mutations in bronchoepithelial cells. Mutations of the p53 gene were tested for by fluorescence-based single-strand conformation polymorphism (FSSCP), cloning-sequencing and immunostaining techniques. Out of 10 tissue samples that demonstrated overexpression of p53 protein by immunostaining, nine (90%) exhibited point mutations and eight (80%) exhibited heterogeneous point mutations of the p53 gene. The mutations found in pulmonary fibrosis were scattered throughout the central part of the p53 gene, and both guanine (G):cytosine (C) to adenine (A):thymine (T) and A:T to G:C transitions were frequently observed. In conclusion, frequent heterogeneous point mutations of the p53 gene were detected in pulmonary fibrosis. These mutations may have resulted from several types of deoxyribonucleic acid damage that occurred in bronchoepithelial cells and this may explain previous findings of a very high incidence of lung cancer complicating pulmonary fibrosis.

Entities:  

Mesh:

Year:  1998        PMID: 9877499     DOI: 10.1183/09031936.98.12061404

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

Review 1.  MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis.

Authors:  Keiko Mizuno; Hiroko Mataki; Naohiko Seki; Tomohiro Kumamoto; Kazuto Kamikawaji; Hiromasa Inoue
Journal:  J Hum Genet       Date:  2016-08-04       Impact factor: 3.172

2.  Role of p53 in the chronic pulmonary immune response to tangled or rod-like multi-walled carbon nanotubes.

Authors:  Katherine S Duke; Elizabeth A Thompson; Mark D Ihrie; Alexia J Taylor-Just; Elizabeth A Ash; Kelly A Shipkowski; Jonathan R Hall; Debra A Tokarz; Mark F Cesta; Ann F Hubbs; Dale W Porter; Linda M Sargent; James C Bonner
Journal:  Nanotoxicology       Date:  2018-10-14       Impact factor: 5.913

3.  Interstitial lung disease is associated with an increased risk of lung cancer in systemic sclerosis: Longitudinal data from the Canadian Scleroderma Research Group.

Authors:  Lama Sakr; Marie Hudson; Mianbo Wang; Elie Younanian; Murray Baron; Sasha Bernatsky
Journal:  J Scleroderma Relat Disord       Date:  2018-04-10

4.  Genetic analysis of sporadic and familial interstitial pneumonia.

Authors:  David A Schwartz
Journal:  Proc Am Thorac Soc       Date:  2008-04-15

5.  Idiopathic pulmonary fibrosis and cancer: do they really look similar?

Authors:  Carlo Vancheri
Journal:  BMC Med       Date:  2015-09-24       Impact factor: 8.775

6.  Pulmonary adenocarcinoma mutation profile in smokers with smoking-related interstitial fibrosis.

Authors:  Andrea Primiani; Dora Dias-Santagata; A John Iafrate; Richard L Kradin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-05-24

Review 7.  Measuring Surgery Outcomes of Lung Cancer Patients with Concomitant Pulmonary Fibrosis: A Review of the Literature.

Authors:  Taichiro Goto
Journal:  Cancers (Basel)       Date:  2018-07-04       Impact factor: 6.639

8.  Clinical analysis of interstitial pneumonia after surgery for lung cancer.

Authors:  Taku Okamoto; Masashi Gotoh; Daiki Masuya; Takashi Nakashima; Dage Liu; Kotaro Kameyama; Shinya Ishikawa; Yasumichi Yamamoto; Cheng-Long Huang; Hiroyasu Yokomise
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2004-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.